Skip to main content

Table 1 Characteristics of the clinical samples included in this study

From: Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer

   EV-RNA
isolation
TRIFic CD9
Analysis
Target gene
analysis
Mutation
Analysis
Variant Allele
Frequency
  # Primary
tumor
Mutation in
primary tumor
Plasma
Input
(mL)
Yielda
(ng)
CD9-EV
Europiuma
(count ×  105)
GAPDHa
(cp ×  104)
Target
genea
(cp ×  102)
MT|WT
cpa in
EV-RNA
EV-RNA
(%)
Primary
Tumor
(%)
cfDNAc
(%)
Cohort I 1 Cholangio
Carcinoma
KRAS G12D
(c.35G > A)
0.8 646 1.1 2.8 7.8 0|600 0 40 0
2 Colorectal
Carcinoma
PIK3CA H1047R
(c.3140A > G)
0.7 908 3.7 0.2 0 0|0 0 38 2.7
3 Breast Cancer PIK3CA H1047L
(c.3140A > T)
0.8 301 2.9 4.1 6.7 0|432 0 26 0
4 Melanoma BRAF V600E
(c.1799 T > A)
0.8 1073 1.9 1.6 2.1 0|395 0 3 1
5b Colorectal
Carcinoma
KRAS G13D
(c.38G > A)
1.3 372 8.4 5.3 10 202|1161 15 60 64.5
6 Colorectal
Carcinoma
KRAS G12D
(c.35G > A)
0.8 250 2.5 0.9 3.1 0|315 0 44 7.3
8 Melanoma BRAF V600E
(c.1799 T > A)
0.7 820 4.9 6.4 8.8 0|475 0 64 35.7
9 Melanoma BRAF V600E
(c.1799 T > A)
0.65 205 1.5 2.2 2.6 0|373 0 70 4.2
13 NSCLC EGFR T790M
(c.2369C > T)
0.8 473 1.2 1 0.2 0|0 0 17 0.9
14 Melanoma BRAF V600E
(c.1799 T > A)
0.8 655 0.8 1.5 1.9 0|410 0 56 5.8
15b NSCLC EGFR T790M
(c.2369C > T)
1.05 368 4.1 2.7 3 288|938 24 65 26.3
16 Melanoma BRAF V600E
(c.1799 T > A)
0.8 137 1.2 5.3 6.6 0|756 0 50 0
Cohort II 17 NSCLC KRAS G12C
(c.34G > T)
0.9 130 5.6 1.9 5.9 0|673 0 32 0.5
18 Melanoma BRAF V600E
(c.1799_1800delinsAA)
0.9 154 3.3 1.2 1.3 0|184 0 50 4.4
19 Melanoma BRAF V600K
(c.1798_1799delGTinsAA)
0.6 174 4.3 1.8 3.1 0|556 0 38 2.6
20 Colon
Carcinoma
KRAS G12D
(c.35G > A)
0.9 414 3.1 3.6 1.1 0|2322 0 45 4.5
21b Colon
Carcinoma
KRAS G13D
(c.38G > A)
0.9 487 4.8 3.6 1.1 34|1521 2.2 40 23.8
22 Rectum-carcinoma KRAS G12V
(c.35G > T)
1 202 4.4 1.3 3.5 0|511 0 UNK 0.9
23 Colon
Carcinoma
KRAS G13D
(c.38G > A)
1 154 9.6 3.0 7.7 0|949 0 50 2.3
24 Melanoma BRAF V600K
(c.1798_1799delGTinsAA)
0.9 294 3.3 5.0 8.6 0|786 0 55 0.9
  1. a per mL plasma
  2. b Mutant EV-RNA transcripts detected
  3. c cfDNA analyses have previously been performed and described (van Dessel, L. F. et al. Mol Oncol, doi:https://doi.org/10.1002/1878-0261.12037 (2017)
  4. VAF Variant Allele Frequency, EV Extracellular Vesicle(s), NSCLC: Non-Small Cell Lung Cancer, UNK Unknown, MT Mutant, WT Wild-type, cp: copies